Glitazones in the treatment of cardiovascular risk factors

Fundam Clin Pharmacol. 2007 Nov:21 Suppl 2:7-13. doi: 10.1111/j.1472-8206.2007.00531.x.

Abstract

This review focuses on the recent advances on the role of the nuclear receptor peroxisome proliferator-activated receptor gamma in the modulation of vascular lipid homeostasis and the inflammatory response and the potential role of these activities in the modulation of metabolic and cardiovascular disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Atherosclerosis / etiology
  • Atherosclerosis / prevention & control
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol / metabolism
  • Clinical Trials as Topic
  • Humans
  • Macrophages / drug effects
  • Macrophages / metabolism
  • PPAR gamma / agonists
  • PPAR gamma / metabolism
  • Risk Factors
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / pharmacology
  • Thiazolidinediones / therapeutic use*

Substances

  • PPAR gamma
  • Thiazolidinediones
  • Cholesterol